Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study
D. A. Mahler, M. Decramer, A. D'Urzo, H. Worth, T. White, V. Alagappan, H. Chen, K. Kulich, N. Gallagher, D. Banerji (Hanover, East Hanover, United States Of America; Leuven, Belgium; Toronto, Canada; Fürth, Germany; Basel, Switzerland; Horsham, United Kingdom)
Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings
Session: Asthma and COPD management: novel clinical findings
Session type: Poster Discussion
Number: 3635
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. A. Mahler, M. Decramer, A. D'Urzo, H. Worth, T. White, V. Alagappan, H. Chen, K. Kulich, N. Gallagher, D. Banerji (Hanover, East Hanover, United States Of America; Leuven, Belgium; Toronto, Canada; Fürth, Germany; Basel, Switzerland; Horsham, United Kingdom). Once-daily QVA149 demonstrates superior improvements in patient-reported dyspnea compared to tiotropium in patients with moderate-to-severe COPD: The BLAZE study. Eur Respir J 2013; 42: Suppl. 57, 3635
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: